Abstract
Azithromycin is the first member of a new class called the azalides. Its distribution in gastric tissues was studied in 27 patients (mean age 66 years) with proven gastric cancer due to be resected. Five groups of patients received a single 500 mg oral dose of azithromycin 24, 48, 72, 96 or 120 h pre-operatively. Samples of blood, gastric juice, mucus and gastric tissue were taken and azithromycin assayed by high performance liquid chromatography. There was an increase in the level of azithromycin in gastric juice up to the 73–96 h period reaching a median peak of 0.20 µg/ml. There were higher levels of azithromycin in gastric mucus (approximately double the maximum attained in gastric juice) at each of the time periods to 120 h after the dose of azithromycin. Much higher levels were seen in the gastric tissue (median peak of 4.6 µg/g), which were statistically significant compared with gastric juice for the first two time periods (24–48 h, p=0.005; 49–72 h, p=0.012). Concentrations seen in the gastric tissue specimens were between five- and 10-fold greater than those seen in gastric mucus, and approximately 20-fold greater than the levels seen in gastric juice at each of the time periods after dosing. It is concluded that remarkably high levels of azithromycin are found in gastric tissue within 24 h of a 500 mg oral dose and that these levels persist over a five-day period. There exists a significant concentration gradient from gastric tissue to gastric juice. Such levels may be advantageous in the therapy ofHelicobacter pylori infections.
Similar content being viewed by others
References
Bright GM, Nagel AA, Bordner J, Desai KA, Dibrino JN, Nowakowska J, Vincent L, Watrous RM, Sciavolino FC: Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivative; a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 1988, 41: 1029–1047.
Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987, 31: 1939–1947.
Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA: Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 1987, 31: 1948–1954.
Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 73–82.
Gladue RP, Bright GM, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Journal on Chemotherapy of Infectious Diseases and Malignancies 1989, 1, Supplement 1: 405.
Axon AT:Campylobacter pylori — therapy review. Scandinavian Journal of Gastroenterology 1989, Supplement, 160: 35–38.
Graham DY, Klein PD, Opekun AR, Smith K, Polasani RR, Evans DJ Jr, Evans DG, Alpert LC, Michaletz PA, Yoshimura HH: In vivo susceptibility ofCampylobacter pylori. American Journal of Gastroenterology 1989, 84: 233–238.
McNulty CA, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations againstCampylobacter pylori in gastric mucosa. Journal of Antimicrobial Chemotherapy 1988, 22: 729–738.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, J.D., Jones, J.A. & Morris, D.L. Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur. J. Clin. Microbiol. Infect. Dis. 10, 862–864 (1991). https://doi.org/10.1007/BF01975843
Issue Date:
DOI: https://doi.org/10.1007/BF01975843